Michael J. Emanuele

The paper identifies Cdk1 and PP2A as a molecular switch that controls the degradation of E2F7 and E2F8, ensuring timely transcriptional reprogramming during the cell cycle.

This study shows USP7 inhibition disrupts proteostasis and tumor growth in triple negative breast cancer by stabilizing E3 ubiquitin ligases and affecting DNA repair pathways.

This paper reveals the structural basis of NSD2 degradation via SCF-FBXO22 recruitment, showing how aldehyde-based degraders induce conformational changes for covalent binding and efficient protein degradation.

This study identifies multi-level molecular changes in ER-positive breast cancer cells treated with palbociclib, revealing feedback loops and alternative splicing that suggest new therapeutic strategies.

The paper determines the structure of Cyclin F-Skp1 complex bound to E2F1 peptide, revealing differences in substrate-binding site and electrostatic interactions compared to Cyclin A.

This study identifies molecular determinants of USP18's specificity for ISG15 through comparative analysis with its paralog USP41, revealing structural features essential for enzymatic activity.

This study identifies USP37 as a deubiquitinase that prevents premature replisome disassembly by deubiquitinating MCM7, ensuring genome stability and normal cell cycle progression.

The paper uses proteomics and PLK1 inhibition to identify proteins degraded at G2/M, showing PLK1's role in coordinating proteolysis via SCF ligases and linking AKAP2 to cell cycle control.

This study shows that enhancing the adaptive IRE1 UPR pathway in T cells improves tumor control by reducing mitochondrial toxicity and chronic ER stress.